General information

Announcements(1)

Program

Sessions

Search presentations

Download PDF for print

Timetable

Mon. Mar 17, 2025

Tue. Mar 18, 2025

Wed. Mar 19, 2025

web_header_en.png

web_icon.png

Profile management

Announcements

Bookmark

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

PPARα as a Therapeutic Target in Schizophrenia

It is essential to develop new technologies and to promote drug discovery from new perspectives for the progression of the diagnostics and therapeutics for CNS diseases. This symposium will address the following topics as new research findings aimed at social implementation. Dr. Yamamoto has succeeded in developing the visualization of ATP dynamics in live mice.This will make it possible to visualize ATP in various organs and is expected to greatly advance the elucidation of the pathophysiology of CNS diseases. Dr. Miwa has found common signs in CNS disorders based on a unique evaluation index of EEG data. Focusing on schizophrenia and autism spectrum disorders, he will mention the possibility of EEG diagnosis. Dr. Naganuma focuses on the histaminergic system as a drug target for hypersomnia. He will discuss new perspectives for the treatment of hypersomnia. Dr. Maekawa discovered the importance of glial cell function regulated by lipid-related molecules in the pathogenesis of schizophrenia. Based on this finding, she has identified new drug targets and is conducting translational research. In this symposium, we will share with the participants the latest findings on the development of diagnostic and therapeutic methods for CNS disorders and deepen the discussion on the future development of this research area.

Innovative Approaches to CNS Disorders: from Diagnosis to Treatment

APPW2025

Presentation Information

[1S09a-4]PPARα as a Therapeutic Target in Schizophrenia

Login required to view

Comment